Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2025 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

WARREN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful...
January 13, 2025 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

On track to submit Anaphylm™ (epinephrine) Sublingual Film NDA in Q1 2025Actively recruiting subjects in the Anaphylm pediatric clinical trialSuccessfully completed AQST-108 (epinephrine) Topical Gel...
December 19, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
December 02, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

Reaffirms New Drug Application (NDA) first quarter 2025 submission guidanceConfirms no additional adult clinical trials are necessary prior to NDA submission Commenced pediatric trial in the U.S. and...
November 12, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WAQRREN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful...
November 04, 2024 16:36 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam)...
October 25, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting

Initial placement or subsequent movement of Anaphylm showed no impact on epinephrine pharmacokinetics (PK) or pharmacodynamics (PD), with all results comparable to epinephrine injectionData...
October 24, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film

Completed OAS challenge study meets both primary and secondary endpointsDemonstrates rapid resolution of allergen-related symptoms beginning two minutes after administration Pharmacokinetic (PK)...
October 21, 2024 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful...
September 27, 2024 08:30 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual FilmOutlines the development strategy...